Description:Ponatinib hydrochloride is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of leukemia, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It selectively targets BCR-ABL, including the T315I mutation, which is resistant to many other therapies. The compound is characterized by its ability to inhibit multiple kinases involved in cancer cell proliferation and survival. Ponatinib hydrochloride is typically administered orally and is known for its potent efficacy, although it may also present a risk of serious side effects, including cardiovascular events and hematologic toxicities. The hydrochloride salt form enhances its solubility and stability, facilitating its formulation for therapeutic use. In terms of chemical properties, ponatinib has a complex structure that includes a pyrimidine core and various functional groups that contribute to its biological activity. As with any medication, its use should be closely monitored by healthcare professionals to manage potential adverse effects and ensure optimal therapeutic outcomes.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.